Bezuclastinib
As of the edition of 20 October 2026, Bezuclastinib is a small molecule: in active development; acts on KIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 7, 0 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 2 | 4 | 1 | 3 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cogent Biosciences | Lead sponsor of trials |